Semnur Pharmaceuticals Inc
What Do They Do?
Develops non-opioid pain treatments, including an injectable gel candidate for sciatica, for patients with acute and chronic pain.
10-K for FY2025, filed Feb 27, 2026
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 27, 2026
Who Are Their Customers?
Plans to market SP-102 to pain specialists, neurologists and select health care providers through Scilex’s sales representatives, with distribution planned through a third-party delivery provider.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$4.3MView ↗
- ▲ +335% (Loss)
- vs −$999K in Q2 FY2025
-
Mar 17, 2026
CEO Jaisim Shah resigned; Henry Ji was appointed CEO and president.
Sources
8-K, filed Mar 17, 2026
On March 13, 2026, Jaisim Shah, Chief Executive Officer and President of Semnur Pharmaceuticals, Inc. (the “Company”), notified the…View ↗
From acquisition search to drug development
The older report describes searching for a business to combine with in technology, hospitality or consumer services; the latest describes developing non-opioid treatments for acute and chronic pain.
10-K for FY2022, filed Mar 17, 2023 10-K for FY2025, filed Feb 27, 2026We are focused on identifying unique business concepts with high-performing organizations that have both aspirations to accelerate growth…View ↗
We are a late-stage clinical biopharmaceutical company focused on developing and commercializing innovative non-opioid pain management…View ↗
Loading...
